Metastatic Nonsmall Cell Lung Cancer Clinical Trial
Official title:
Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer
The study aims include: - Exploring potential predictive molecular profiles to immunotherapy/chemotherapy - Investigating the role of circulating tumor DNA as a dynamic biomarker during immunotherapy/chemotherapy - Identifying possible resistance mechanisms to immunotherapy/chemotherapy Materials and methods: Approximately 150 patients diagnosed with metastatic NSCLC assigned for immunotherapy or chemotherapy will be candidates for inclusion during a 1-2 years period. A comprehensive molecular profiling will be made from the diagnostic biopsy. Before every treatment-cycle a blood sample will be taken to quantify ctDNA. At time of progressive disease during/after first line treatment, patients will be asked to participate in a new biopsy and a comprehensive molecular profiling will be performed. The tissue and blood samples collected will be stored in a biobank. Clinical data will be collected to perform a comprehensive database. Analysis: Potentially predictive molecular profiles for immunotherapy/chemotherapy will be found by comparison of treatment outcome for patients with specific molecular characteristics. Through quantification of ctDNA during treatment and upon progression, the role of ctDNA as a dynamic biomarker will be further strengthened. Differences in molecular profiles pre- and post-treatment may reveal resistance mechanisms to treatment. Molecular profiling on progression can be valuable in second-line treatment guidance.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
| Recruiting |
NCT06228482 -
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
|
Phase 1 | |
| Completed |
NCT03415126 -
A Study of ASN007 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT03825510 -
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
|
Phase 2 |